Treatment Outcomes and Prognostic Factors for Patients With Medulloblastoma Having Defined Molecular Subtypes
MB is a heterogeneous disease that requires the integration of clinical and molecular features for defined risk stratification to facilitate individualized treatment. In this study, we found that residual disease after RT, fewer than 6 cycles of chemotherapy, and high-risk NCCN risk stratification were independent adverse prognostic factors for patients with MB.
Authors
- Shuang Liu (ORCID: https://orcid.org/0000-0003-3301-6925)
- Yiyuan Li (ORCID: https://orcid.org/0000-0002-5255-7463)
- Xiaoyang Sun
- Xuejiao Shi
- Mawei Jiang (ORCID: https://orcid.org/0000-0003-2866-4709)
Institutions
- Shanghai Jiao Tong University (CN)
- XinHua Hospital (CN)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1016/j.adro.2025.101796
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Shanghai Municipal Health Commission
- Shanghai Jiao Tong University